Blog

2), metastatic site, and second-line treatment in sufferers withKRASwild-type vs.KRASmutant samples. types. == Outcomes == PNA-PCR was a lot more delicate in detectingKRASmutations than sequencing (41% vs. 30%, p < 0.001).KRASmutations were more frequent in tumor tissues than in plasma (sequencing, 38% vs. 17%, p < 0.001; PNA-PCR, 47% vs. 31%, p < 0.001). Median Operating-system was shorter inKRAS-mutated sufferers thanKRASwild-type sufferers regularly, separate in the tissues and assay tested; the biggest difference is at plasma samples examined by PNA-PCR (KRASmutated vs. wild-type: 15.7 vs. 19.1 months, p = 0.009). Simply no association was observed and various other final results betweenKRASstatus. When tumor and plasma outcomes jointly had been regarded, median Operating-system in patients grouped as tissues/plasmaKRASnegative/negative, tissues/plasmaKRASdiscordant, and tissues/plasmaKRASpositive/positive had been 21.0, 16.9 and 15.4 months, respectively (p = 0.008). == Conclusions == KRASmutation position is certainly of prognostic relevance in sufferers with mCRC.KRASmutations in both tumor plasma and tissues certainly are a strong prognostic marker for poor final results. == Electronic supplementary materials == Rabbit polyclonal to TSP1 The web version of the content (doi:10.1186/s13046-014-0104-7) contains supplementary materials, which is open to authorized users. Keywords:Kras, Colorectal cancers, Prognosis == History == K-RAS is certainly an integral oncogene person in the mitogen-activated proteins kinase signaling pathway [1,2]. Analysis mainly in colorectal cancers displays thatKRASmutations take place most in codons 12 and 13 typically, generally precede the introduction of malignancy [3,4], and are maintained in secondary disease sites [5]. Several studies have addressed the prognostic-predictive value ofKRASmutational status in colorectal cancer patients [6]. It is now well established thatKRASmutations are the main reason for resistance to anti-epidermal growth factor receptor (EGFR) antibodies [7,8], and account for nearly two-thirds of EGFR downstream effector alterations in colorectal cancer [9]. KRASmutations are also a predictive factor for response to tyrosine kinase inhibitors [10]. Clinical data regarding the prognostic value ofKRASmutations in patients with metastatic colorectal cancer (mCRC) treated with chemotherapy remain inconclusive [1]. Most studies addressing this question were retrospective or included limited patient numbers [6]. Some prospective studies also reached discordant conclusions [11] because the data were derived from the control arm of randomized trials of anti-EGFR antibodies as first-line treatment in combination with chemotherapy. In these studies, cross-over to anti-EGFR therapy was permitted or patients received anti-EGFR therapy after study treatment, making prognostic interpretation difficult. The prognostic-predictive relevance ofKRASalterations to chemotherapy alone in mCRC has still to be determined in a large patient sample. Although direct sequencing is widely accepted as the gold standard FAAH inhibitor 1 for mutation screening [12], this method requires that 25% of DNA alleles in the sample are mutated [6,13]. Over the past five years, several new techniques, including peptide-nucleic-acid-mediated polymerase chain reaction clamping (PNA-PCR), have emerged. These methods have higher sensitivity than direct sequencing, and permit the detection of lower mutation frequencies (1%-5%) FAAH inhibitor 1 [14-16]. Routine assessment ofKRASmutational status is generally performed in tumor samples and used to personalize treatment in patients with mCRC [14,17]. Oh et al. combined PNA-Mediated Asymmetric PCR with Melting Curve Analysis to detect several types of low-level FAAH inhibitor 1 KRAS mutations in colorectal cancer tissues [18]. However, a recent review of 11 clinical studies, reported that 29%-100% of patients presented with the sameKRASmutation in both blood and tumor samples suggesting that blood samples may also be suitable for determiningKRASstatus [19-21]. One study performed by Yu et al. has showed that PNA-PCR powered by pyrosequencing had the potenial to screen plasma KRAS mutations with high sensitivity and accuracy in pancreatic cancer patients [22]. We hypothesized thatKRASmutation status determined using PNA-PCR in tumor tissue and/or blood could be a powerful and easy-to-perform approach for planning treatment in patients with advanced colorectal cancer. In the present study, we analyzed the impact ofKRASstatus, determined by both direct sequencing and PNA-PCR methods in tumor and matched plasma samples, on clinical outcome in a large consecutive mono-institutional series of advanced colorectal cancer patients. All patients received oxaliplatin-based or irinotecan-based chemotherapy as first-line and second-line treatment, but never received biologic therapy. == Methods == == Study design == Between January 2007 and June 2011, 566 consecutive patients with mCRC were admitted to the Affiliated Hospital Cancer Center of the Academy of Military Medical Sciences in Beijing and were treated with systemic chemotherapy. 416 patients meeting the inclusion criteria were enrolled into this study retrospectively. The study was approved by the ethical committee of Affiliated Hospital, Academy of Military Medical Sciences (ID-2011-91). All patients provide their written informed consent to participate in this study. The inclusion criteria were: completion of 2 cycles of oxaliplatin-based or irinotecan-based chemotherapy as first-line.